S. Korean Court Nears Final Ruling on $35M Claim Against PMI, BAT, KT&G

Apr.23.2025
S. Korean Court Nears Final Ruling on $35M Claim Against PMI, BAT, KT&G
South Korea’s National Health Insurance Service (NHIS) filed a lawsuit seeking about 50 billion won (approximately USD 35 million) in damages against Korea Tobacco & Ginseng (KT&G), Philip Morris International Korea, and British American Tobacco Korea, arguing that these companies should reimburse the treatment costs for patients with smoking-related cancers . Originally lodged in April 2014, the case has spanned 11 years and has now entered the final oral-argument phase at the appellate level.

Key points:

Background and scale of the case: The National Health Insurance Service (NHIS) of South Korea has filed a lawsuit since 2014 against KT&G, Philip Morris International (PMI) Korea (Philip Morris Korea), British American Tobacco Korea (BAT Korea), and others, seeking compensation of 533 billion Korean won (approximately 38 million US dollars). The reason for the lawsuit is that NHIS has paid for treatment expenses for patients suffering from smoking-related cancers.

 

First instance and second instance results: The first instance court found it difficult to confirm a direct causal relationship between smoking and cancer, supporting the tobacco company's position. In the second instance, the healthcare organization presented testimonies from an 86-year-old patient, asserting that there were no other contributing factors to their cancer besides a long history of smoking, in an attempt to strengthen the causal relationship.

 

Controversy over ingredients and court ruling: The first trial also involved a dispute over the responsibility of tar and nicotine in tobacco. The court believed that nicotine is a core attribute of tobacco products and cannot be used as a basis for establishing liability for infringement.


According to N. News, the South Korean National Health Insurance Service (NHIS) has entered the final stage of a lawsuit seeking approximately 500 billion Korean won (approximately 35 million US dollars) in compensation from multiple tobacco companies. The Chief Judge of the Civil 6-1 Division of the Seoul High Court will hold a final round of debates on May 22, after which the date for the ruling on the case will be determined.

 

The case has been ongoing for 11 years since it was filed in April 2014. NHIS is seeking a claim of approximately 533 billion Korean won from KT&G, Philip Morris International (PMI) Korea, and British American Tobacco Korea to reimburse the medical expenses paid by the organization from 2003 to 2013 for 3,465 patients with lung cancer (small cell carcinoma, squamous cell carcinoma) and throat cancer (squamous cell carcinoma).

 

The central dispute of the lawsuit focuses on the causal relationship between smoking and the development of cancer, as well as whether tobacco companies should be held legally responsible for this.

 

In November 2020, the Seoul Central District Court ruled in the first instance that it is difficult to establish a direct causal relationship between smoking and cancer, therefore rejecting all claims of NHIS. The court believed that cancer may be caused by genetics, lifestyle, or other environmental factors. In the first instance, NHIS also argued that tobacco companies did not effectively reduce tar and nicotine levels, but instead added flavor enhancers to enhance the taste. However, the court considered that consumers actively seek the pharmacological sedative effects of nicotine, so this component is inherent to tobacco products and it is difficult to hold tobacco companies accountable for it.

 

NHIS subsequently filed an appeal in December of the same year. In the second trial, NHIS submitted a statement from lung cancer patient A, who is over 80 years old, as additional evidence, attempting to prove that A's lung cancer had no other obvious causes besides smoking. The statement pointed out that A had been smoking for decades since his twenties, although he quit smoking in the late 1990s, he was diagnosed with lung cancer in 2010, and had no relevant family medical history.

 

Currently, South Korean judicial authorities tend to attribute the responsibility for diseases caused by smoking to individuals. In 2014, the South Korean Supreme Court ruled in a similar lawsuit filed by 30 patients against KT&G that smokers must bear the health consequences themselves and did not support their compensation claim.

 

In 1998, the government of all 50 states in the United States jointly filed a lawsuit against tobacco companies including Philip Morris International (PMI) and Reynolds Tobacco, eventually reaching a $246 billion settlement agreement. This result was partially influenced by the "Tobacco Industry Documents," released by internal researchers in 1994, prompting the public to reassess the addictive nature and harm of tobacco products.

 

NHIS believes that this lawsuit is not only legally significant but also helps to raise public awareness on smoking cessation. NHIS is currently promoting a "1 million national support signature campaign" in order to create public opinion support for the upcoming second trial judgment.

 

The tobacco company, on the other hand, stated that they will participate in the second appeal process "honestly".

 

It is reported that the National Health Insurance Service (NHIS) of Korea is a national public institution under the Ministry of Health and Welfare, responsible for the nationwide operation and management of health insurance. Its main duties include providing medical insurance services to the public, collecting insurance premiums, and overseeing settlements with medical institutions.

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Australia Adds 6-Methylnicotine to Schedule 9 Prohibited Substances, Effective October 1
Australia Adds 6-Methylnicotine to Schedule 9 Prohibited Substances, Effective October 1
Australia's Therapeutic Goods Administration published a final decision on September 25 to classify 6-methylnicotine as a Schedule 9 prohibited substance under the Poisons Standard, effective October 1, 2026. TGA said the chemical has been reported in e-cigarette liquids sold in Australia and marketed as nicotine-free or nicotine alternatives, while evidence also indicates its use in preparations such as oral pouches. The government originally proposed a Schedule 7 classification but ultimately adopted the stricter Schedule 9 designation, citing acute toxicity, dependence risk, use in unapproved consumer products and misleading marketing.
News
Sep.29 by 2Firsts Perspectives
South Korea's Tobacco Plan Excludes 6-Methyl Nicotine as Customs Tightens Import Controls and Analog Liquid Imports Fall 83%
South Korea's Tobacco Plan Excludes 6-Methyl Nicotine as Customs Tightens Import Controls and Analog Liquid Imports Fall 83%
South Korea's government unveiled its first Tobacco Harm Management Basic Plan for 2027–2031 on October 29, 2026, proposing broader testing of vaping and heated tobacco products while excluding nicotine analogs such as 6-methyl nicotine. Synthetic nicotine came under tobacco regulation on April 24, and a June investigation found 6-methyl nicotine in 12 liquid inhalation products marketed as nicotine-free. Customs data released in September showed that imports of nicotine analog solutions fell 83.3%, from 12 metric tons in January–April to 2 metric tons in May–August. By September 20, imports had reached approximately 15 metric tons for the year, with 99.99% originating from China. Customs authorities have tightened pre-clearance testing and supply-chain documentation requirements, while the MFDS expects to complete its assessment of nicotine analog hazards by the end of 2026.
Regulations
Nov.04
U.S. Health Groups Seek to Overturn FDA Enforcement Discretion for Pending PMTAs as Altria's Helix, NJOY and AVM Move to Intervene
U.S. Health Groups Seek to Overturn FDA Enforcement Discretion for Pending PMTAs as Altria's Helix, NJOY and AVM Move to Intervene
American Vapor Manufacturers (AVM) and Altria subsidiaries Helix Innovations and NJOY filed separate motions on October 7, 2026, seeking to intervene on the FDA's side in a lawsuit challenging its enforcement guidance for certain e-cigarette and nicotine pouch products with pending premarket tobacco product applications (PMTAs). Seven public health and tobacco-control organizations, including the Campaign for Tobacco-Free Kids, sued the agency in July to overturn the policy. AVM argues that vacating the guidance could disrupt orders, inventory, retail distribution and investments in regulatory submissions.
Regulations
Oct.09
Wisconsin Vape Directory One Year On: Retailer Reports Four Store Closures and 70% Staff Cuts
Wisconsin Vape Directory One Year On: Retailer Reports Four Store Closures and 70% Staff Cuts
Wisconsin's electronic vaping device directory has been fully enforced for more than a year, and local vape retailers say the reduced range of eligible products has contributed to declining sales, store closures and layoffs. Johnny Vapes owner Ben Hall said he has closed four of seven locations and cut about 70% of his staff. State law bars the sale of vaping devices not listed on the Wisconsin Department of Revenue directory and allows penalties of $1,000 per day for each unlisted device sold or offered for sale. In April 2026, the U.S. Court of Appeals for the Seventh Circuit allowed enforcement of the law to continue.
Regulations
Oct.10
FDA Appoints Former Tobacco Enforcement Deputy Jessica Zeller as Director as Agency Weighs PMTA Framework Changes
FDA Appoints Former Tobacco Enforcement Deputy Jessica Zeller as Director as Agency Weighs PMTA Framework Changes
The U.S. Food and Drug Administration (FDA) has named Jessica Zeller director of the Center for Tobacco Products' (CTP) Office of Compliance and Enforcement (OCE), effective November 1, 2026. Zeller, the office's inaugural deputy director, returns from medical device manufacturer Edwards Lifesciences with more than 20 years of regulatory and legal experience. The appointment follows CTP leadership changes and adjustments to tobacco regulation. Bret Koplow became permanent CTP director in September; the FDA revised enforcement priorities for unauthorized e-cigarettes and nicotine pouches in May and announced faster PMTA review procedures. On September 28, the agency said it would evaluate changes to the existing PMTA regulatory framework, including potential rulemaking to replace it.
FDA
Oct.20 by 2Firsts Perspectives
Product | Philip Morris Launches TEREA Bold Red and Bold Black in Germany With Level-10 Tobacco Intensity at €8 per Pack
Product | Philip Morris Launches TEREA Bold Red and Bold Black in Germany With Level-10 Tobacco Intensity at €8 per Pack
Philip Morris International (PMI) introduced TEREA Bold Red and Bold Black heated tobacco sticks in Germany in October 2026, both carrying a brand-rated tobacco-flavor intensity of 10, the highest level in the country's TEREA portfolio. Bold Red features leather and warm woody notes, while Bold Black combines woody and subtle floral notes. Both are sold in 20-stick packs at €8, approximately 2.6% above standard TEREA products. Germany's TEREA range now includes 11 flavor variants, alongside a separate 26-stick XL format priced at €10. IQOS Germany announced the new products on October 12, followed by a phased retail rollout from late October and an IQOS Club campaign running through December.
product
Nov.02